80 related articles for article (PubMed ID: 20977577)
1. Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas.
Irwin N; McKinney JM; Bailey CJ; Flatt PR; McClenaghan NH
Diabetes Obes Metab; 2010 Dec; 12(12):1066-71. PubMed ID: 20977577
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism.
Brennan L; Hewage C; Malthouse JP; McClenaghan NH; Flatt PR; Newsholme P
FEBS J; 2006 Nov; 273(22):5160-8. PubMed ID: 17054712
[TBL] [Abstract][Full Text] [Related]
3. Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
Ball AJ; Flatt PR; McClenaghan NH
Eur J Pharmacol; 2000 Nov; 408(3):327-33. PubMed ID: 11090651
[TBL] [Abstract][Full Text] [Related]
4. Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not transcription of K(ATP) channel components.
Ball AJ; McCluskey JT; Flatt PR; McClenaghan NH
Pharmacol Res; 2004 Jul; 50(1):41-6. PubMed ID: 15082027
[TBL] [Abstract][Full Text] [Related]
5. Interaction of glibenclamide and metformin at the level of translation in pancreatic β cells.
Wang Q; Cai Y; Van de Casteele M; Pipeleers D; Ling Z
J Endocrinol; 2011 Feb; 208(2):161-9. PubMed ID: 21084384
[TBL] [Abstract][Full Text] [Related]
6. Effects of sulphonylureas on the volume-sensitive anion channel in rat pancreatic beta-cells.
Best L; Benington S
Br J Pharmacol; 1998 Oct; 125(4):874-8. PubMed ID: 9831927
[TBL] [Abstract][Full Text] [Related]
7. Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure.
McClenaghan NH; Ball AJ; Flatt PR
Biochem Pharmacol; 2001 Mar; 61(5):527-36. PubMed ID: 11239495
[TBL] [Abstract][Full Text] [Related]
8. [Extrapancreatic effects of sulfonylurea compounds. IV. Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro].
Beyer J; Gather W; Schöffling K
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2179. PubMed ID: 4198966
[No Abstract] [Full Text] [Related]
9. Mg(2+)-dependent inhibition of KATP by sulphonylureas in CRI-G1 insulin-secreting cells.
Lee K; Ozanne SE; Hales CN; Ashford ML
Br J Pharmacol; 1994 Feb; 111(2):632-40. PubMed ID: 8004407
[TBL] [Abstract][Full Text] [Related]
10. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets.
Del Guerra S; Marselli L; Lupi R; Boggi U; Mosca F; Benzi L; Del Prato S; Marchetti P
J Diabetes Complications; 2005; 19(1):60-4. PubMed ID: 15642492
[TBL] [Abstract][Full Text] [Related]
11. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronidase-induced inhibition of the insulinotropic action of sulfonylureas, leucine, and glucagon in rodent isolated pancreatic islets.
Macchi IA; Zeytinoğlu FN
Horm Metab Res; 1976 Mar; 8(2):92-6. PubMed ID: 177348
[TBL] [Abstract][Full Text] [Related]
13. Sulphonylurea receptor-1, sulphonylureas and amplification of insulin secretion by Epac activation in β cells.
Nenquin M; Henquin JC
Diabetes Obes Metab; 2016 Jul; 18(7):698-701. PubMed ID: 26584950
[TBL] [Abstract][Full Text] [Related]
14. Glibenclamide treatment recruits beta-cell subpopulation into elevated and sustained basal insulin synthetic activity.
Ling Z; Wang Q; Stangé G; In't Veld P; Pipeleers D
Diabetes; 2006 Jan; 55(1):78-85. PubMed ID: 16380479
[TBL] [Abstract][Full Text] [Related]
15. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase.
Takahashi A; Nagashima K; Hamasaki A; Kuwamura N; Kawasaki Y; Ikeda H; Yamada Y; Inagaki N; Seino Y
Diabetes Res Clin Pract; 2007 Sep; 77(3):343-50. PubMed ID: 17316868
[TBL] [Abstract][Full Text] [Related]
16. [Extrapancreatic effects of sulfonylurea compounds. 3. Studies on the additional blood sugar decreasing and antilipolytic effect of tolbutamide, glibornuride, and glibenclamide on completely pancreatectomized dogs, chronically treated with insulin during acute experiment and following pretreatment with sulfonylurea compounds using small doses of sulfonylurea].
Beyer J; Cordes U; Sell G; Schöffling K
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2176. PubMed ID: 4198965
[No Abstract] [Full Text] [Related]
17. OATP1B3 is expressed in pancreatic β-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide.
Meyer Zu Schwabedissen HE; Boettcher K; Steiner T; Schwarz UI; Keiser M; Kroemer HK; Siegmund W
Diabetes; 2014 Feb; 63(2):775-84. PubMed ID: 24150606
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.
Sawada F; Inoguchi T; Tsubouchi H; Sasaki S; Fujii M; Maeda Y; Morinaga H; Nomura M; Kobayashi K; Takayanagi R
Metabolism; 2008 Aug; 57(8):1038-45. PubMed ID: 18640379
[TBL] [Abstract][Full Text] [Related]
19. The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
Katsumata K; Katsumata Y
Horm Metab Res; 1990 Jan; 22(1):51-2. PubMed ID: 2106472
[No Abstract] [Full Text] [Related]
20. Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells.
McKiney JM; Irwin N; Flatt PR; Bailey CJ; McClenaghan NH
Biol Chem; 2010 Dec; 391(12):1451-9. PubMed ID: 20868233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
